Quoin Pharmaceuticals Ltd. Investing Cash Flow
Quoin Pharmaceuticals Ltd. (QNRX) reported Investing Cash Flow of $8.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $4.02M, a 138.77% increase year-over-year.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $4.12M, a 48.70% increase year-over-year.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$11.27M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $2.54M, a 2.42% decline year-over-year.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for fiscal 2025 was -$4.28M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for fiscal 2024 was -$1.89M, a 186.29% decline from fiscal 2023.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for fiscal 2023 was $2.19M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) investing activities for fiscal 2022 was -$10.15M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.14M 10-Q · filed 2026-08-14 | -$3.13M derived: sum of 3 quarters · filed 2026-08-14 | -$593.77K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.12M 10-Q · filed 2026-05-07 | -$7.15M derived: sum of 2 quarters · filed 2026-05-07 | -$4.61M derived: sum of 3 quarters · filed 2026-05-07 | -$2.93M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$8.73M derived: sum of 2 quarters · filed 2026-03-26 | -$7.05M derived: sum of 3 quarters · filed 2026-08-14 | -$4.28M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.22M derived: sum of 2 quarters · filed 2026-08-14 | $6.99M 10-Q · filed 2025-11-06 | $3.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.45M 10-Q · filed 2026-08-14 | $1.27M derived: sum of 3 quarters · filed 2026-08-14 | $3.88M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.77M 10-Q · filed 2026-05-07 | -$408.32K derived: sum of 2 quarters · filed 2026-05-07 | $2.19M derived: sum of 3 quarters · filed 2026-05-07 | $5.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$577.51K derived: sum of 2 quarters · filed 2026-03-26 | $2.58M derived: sum of 3 quarters · filed 2026-03-26 | -$1.89M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.76M derived: sum of 2 quarters · filed 2025-11-06 | $1.29M 10-Q · filed 2025-11-06 | $3.93M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.31M 10-Q · filed 2025-08-07 | $1.33M derived: sum of 3 quarters · filed 2025-08-07 | $1.33M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$4.47M 10-Q · filed 2025-05-13 | -$1.82M derived: sum of 2 quarters · filed 2025-05-13 | -$1.82M derived: sum of 3 quarters · filed 2025-05-13 | $1.21M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.64M derived: sum of 2 quarters · filed 2025-03-13 | $5.68M derived: sum of 3 quarters · filed 2025-03-13 | $2.19M 10-K · filed 2025-03-13 |
| 2023-09-30 | $821.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $3.04M derived: sum of 2 quarters · filed 2024-11-08 | -$455.68K 10-Q · filed 2024-11-08 | -$455.68K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$456.50K 10-Q · filed 2024-08-08 | -$456.50K derived: sum of 3 quarters · filed 2024-08-08 | -$10.36M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.49M 10-Q · filed 2024-05-09 | -$3.49M derived: sum of 2 quarters · filed 2024-05-09 | -$13.39M derived: sum of 3 quarters · filed 2024-05-09 | -$13.59M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$9.90M derived: sum of 2 quarters · filed 2024-03-14 | -$10.10M derived: sum of 3 quarters · filed 2024-03-14 | -$10.15M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$10.10M derived: sum of 2 quarters · filed 2023-11-09 | -$10.15M 10-Q · filed 2023-11-09 | -$10.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$250.00K 10-Q · filed 2023-08-03 | -$500.00K derived: sum of 3 quarters · filed 2023-08-03 | -$607.50K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$50.00K 10-Q · filed 2023-05-09 | -$300.00K derived: sum of 2 quarters · filed 2023-05-09 | -$407.50K derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$250.00K derived: 10-K 12 month − 6-K 9 month · filed 2023-03-15 | -$357.50K derived: sum of 2 quarters · filed 2023-03-15 | -$625.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$107.50K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-10 | -$375.00K 6-K · filed 2022-11-10 | ||
| 2021-06-30 | -$267.50K 6-K · filed 2022-08-18 | |||
| 2020-12-31 | -$125.00K 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |